1. 718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells. (9th November 2020) Authors: Li, Cong; Fort, Madeline; Liang, Lingming; Moore, Gregory; Bernett, Matthew; Muchhal, Umesh; Osgood, Tao; Yabut, Rodolfo; Kaliyaperumal, Sarav; Harrold, John; Canon, Jude; Rogojina, Anna; Kurmasheva, Raushan; Desjarlais, John; Houghton, Peter; Nolan-Stevaux, Olivier Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A430 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells. (9th November 2020) Authors: Li, Cong; Fort, Madeline; Liang, Lingming; Moore, Gregory; Bernett, Matthew; Muchhal, Umesh; Osgood, Tao; Yabut, Rodolfo; Kaliyaperumal, Sarav; Harrold, John; Canon, Jude; Rogojina, Anna; Kurmasheva, Raushan; Desjarlais, John; Houghton, Peter; Nolan-Stevaux, Olivier Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A760 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗